Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 15Prostatic Neoplasms 10Neoplasms 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Myeloid, Acute 4Triple Negative Breast Neoplasms 3Ovarian Neoplasms 3Myelodysplastic Syndromes 3Endometrial Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Cardiovascular Diseases 3Cardiotoxicity 3Rectal Neoplasms 2Polycystic Ovary Syndrome 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Melanoma 2Lymphoma, Non-Hodgkin 2Leukemia 2Kidney Neoplasms 2Heart Failure 2Head and Neck Neoplasms 2Glioblastoma 2Endometrial Hyperplasia 2Carcinoma, Renal Cell 2Waldenstrom Macroglobulinemia 1Venous Thrombosis 1Urogenital Neoplasms 1Smoking 1

Interventions

evolocumab 1Ezetimibe 1Atorvastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hyperlipoproteinemia Type II × Atorvastatin × Clear all
NCT04862260 2026-03-19

Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma

CHU de Quebec-Universite Laval

Phase EARLY_PHASE1 Active not recruiting
3 enrolled
Gastrointestinal

Hyperlipoproteinemia Type II, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡